Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 43 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MORGAT C, MacGrogan G, Brouste V, Velasco V, et al
    Expression of Gastrin-Releasing Peptide Receptor (GRPR) in Breast Cancer and its Association with Pathological, Biological and Clinical Parameters: A Study of 1432 Primary Tumors.
    J Nucl Med. 2017 Mar 9. pii: jnumed.116.188011. doi: 10.2967/jnumed.116.188011.
    PubMed     Text format     Abstract available


    January 2017
  2. LI L, Wu Y, Wang Z, Jia B, et al
    SPECT/CT Imaging of the Novel HER2-targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.183863. doi: 10.2967/jnumed.116.183863.
    PubMed     Text format     Abstract available


    December 2016
  3. CHAE SY, Kim SB, Ahn SH, Moon DH, et al
    Reply: 18F-fluoroestradiol positron emission tomography to predict response to neoadjuvant treatment in luminal breast cancer.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.185660.
    PubMed     Text format    


    November 2016
  4. FOWLER AM, Linden HM
    Functional Estrogen Receptor Imaging Prior to Neoadjuvant therapy for Primary Breast Cancer.
    J Nucl Med. 2016 Nov 17. pii: jnumed.116.183533.
    PubMed     Text format    


    October 2016
  5. YANG H, Jenni S, Colovic M, Merkens H, et al
    18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.180661.
    PubMed     Text format     Abstract available


    September 2016
  6. CHAE SY, Kim SB, Ahn SH, Kim HO, et al
    A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.178368.
    PubMed     Text format     Abstract available


  7. LEBON V, Alberini JL, Pierga JY, Dieras V, et al
    The rate of distant metastases on FDG-PET/CT at initial staging of breast cancer: comparison between women younger and older than 40 years.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178749.
    PubMed     Text format     Abstract available


    June 2016
  8. DOOT RK
    Invited Perspective for: 18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.175687.
    PubMed     Text format    


    May 2016
  9. MCCONATHY J
    [F-18]Fluciclovine (FACBC) and its Potential Use for Breast Cancer Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.116.175489.
    PubMed     Text format    


  10. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed     Text format    


  11. ULANER GA, Hyman D, Ross D, Corben A, et al
    Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT.
    J Nucl Med. 2016 May 5. pii: jnumed.115.172031.
    PubMed     Text format     Abstract available


  12. CHEN KT, Hu YW
    Letter: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 5. pii: jnumed.116.173641.
    PubMed     Text format    


    April 2016
  13. HUMBERT O, Riedinger JM, Vrigneaud JM, Kanoun S, et al
    18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer.
    J Nucl Med. 2016 Apr 21. pii: jnumed.116.172759.
    PubMed     Text format     Abstract available


  14. JIANG S, Pogue B
    Invited Perspective for: "Near-infrared diffuse optical imaging for early prediction of breast cancer response to neoadjuvant chemotherapy: a comparative study using FDG-PET/CT".
    J Nucl Med. 2016 Apr 21. pii: jnumed.116.174367.
    PubMed     Text format    


  15. TADE FI, Cohen MA, Styblo TM, Odewole OA, et al
    Anti-3-[18F] FACBC (Fluciclovine) PET-CT of Breast Cancer An Exploratory Study.
    J Nucl Med. 2016 Apr 7. pii: jnumed.115.171389.
    PubMed     Text format     Abstract available


    March 2016
  16. LEE HW, Lee HM, Choi SE, Yoo H, et al
    The Prognostic Impact of Early Change in Standardized Uptake Value of 18F-fluorodeoxy-glucose Positron Emission Tomography after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    J Nucl Med. 2016 Mar 31. pii: jnumed.115.166322.
    PubMed     Text format     Abstract available


  17. PINKER K, Riedl C, Ong L, Jochelson M, et al
    Impact of the number of lesions analyzed in metastatic breast cancer on response assessment by 18F-FDG PET/CT using PERCIST.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.166629.
    PubMed     Text format     Abstract available


  18. LI N, Wang X, Lin B, Zhu H, et al
    Clinical Evaluation of 99mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.160572.
    PubMed     Text format     Abstract available


  19. UEDA S, Yoshizawa N, Shigekawa T, Takeuchi H, et al
    Near-infrared diffuse optical imaging for early prediction of breast cancer response to neoadjuvant chemotherapy: a comparative study using FDG-PET/CT.
    J Nucl Med. 2016 Mar 3. pii: jnumed.115.167320.
    PubMed     Text format     Abstract available


    February 2016
  20. FOWLER AM
    Molecular Imaging Approaches for Supplemental Screening in Women at Increased Breast Cancer Risk.
    J Nucl Med. 2016 Feb 9. pii: jnumed.115.171330.
    PubMed     Text format    


  21. SANDSTROM M, Lindskog K, Velikyan I, Wennborg A, et al
    Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients.
    J Nucl Med. 2016 Feb 9. pii: jnumed.115.169342.
    PubMed     Text format     Abstract available


  22. YOOK S, Cai Z, Lu Y, Winnik MA, et al
    Intratumorally Injected 177Lu-Labeled Gold Nanoparticles - Gold Nanoseed Brachytherapy with Application for Neo-Adjuvant Treatment of Locally Advanced Breast Cancer (LABC).
    J Nucl Med. 2016 Feb 4. pii: jnumed.115.168906.
    PubMed     Text format     Abstract available


  23. MCDONALD ES, Clark AS, Tchou J, Zhang P, et al
    Clinical Diagnosis and Management of Breast Cancer.
    J Nucl Med. 2016;57 Suppl 1:9S-16S.
    PubMed     Text format     Abstract available


  24. KENNY L
    The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis.
    J Nucl Med. 2016;57 Suppl 1:89S-95S.
    PubMed     Text format     Abstract available


  25. FOWLER AM, Clark AS, Katzenellenbogen JA, Linden HM, et al
    Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer.
    J Nucl Med. 2016;57 Suppl 1:75S-80S.
    PubMed     Text format     Abstract available


  26. MCDONALD ES, Mankoff DA, Mach RH
    Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment.
    J Nucl Med. 2016;57 Suppl 1:69S-74S.
    PubMed     Text format     Abstract available


  27. MANNING HC, Buck JR, Cook RS
    Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine.
    J Nucl Med. 2016;57 Suppl 1:60S-8S.
    PubMed     Text format     Abstract available


  28. ULANER GA, Riedl CC, Dickler MN, Jhaveri K, et al
    Molecular Imaging of Biomarkers in Breast Cancer.
    J Nucl Med. 2016;57 Suppl 1:53S-9S.
    PubMed     Text format     Abstract available


  29. AVRIL S, Muzic RF Jr, Plecha D, Traughber BJ, et al
    18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.
    J Nucl Med. 2016;57 Suppl 1:34S-9S.
    PubMed     Text format     Abstract available


  30. COOK GJ, Azad GK, Goh V
    Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment.
    J Nucl Med. 2016;57 Suppl 1:27S-33S.
    PubMed     Text format     Abstract available


  31. GROHEUX D, Cochet A, Humbert O, Alberini JL, et al
    18F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    J Nucl Med. 2016;57 Suppl 1:17S-26S.
    PubMed     Text format     Abstract available


  32. VAN ES SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, et al
    Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
    J Nucl Med. 2016;57 Suppl 1:96S-104S.
    PubMed     Text format     Abstract available


  33. GEBHART G, Flamen P, De Vries EG, Jhaveri K, et al
    Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.
    J Nucl Med. 2016;57 Suppl 1:81S-8S.
    PubMed     Text format     Abstract available


  34. BERG WA
    Nuclear Breast Imaging: Clinical Results and Future Directions.
    J Nucl Med. 2016;57 Suppl 1:46S-52S.
    PubMed     Text format     Abstract available


  35. HSU DF, Freese DL, Levin CS
    Breast-Dedicated Radionuclide Imaging Systems.
    J Nucl Med. 2016;57 Suppl 1:40S-5S.
    PubMed     Text format     Abstract available


  36. WAHL RL
    Quo Vadis: PET and Single-Photon Molecular Breast Imaging.
    J Nucl Med. 2016;57 Suppl 1:3S-8S.
    PubMed     Text format    


  37. CZERNIN J, Mankoff D
    Introduction and Overview.
    J Nucl Med. 2016;57 Suppl 1:1S-2S.
    PubMed     Text format    


    January 2016
  38. BREM RF, Ruda RC, Yang JL, Coffey CM, et al
    Breast-specific gamma imaging for the detection of mammographically occult breast cancer in women at increased risk.
    J Nucl Med. 2016 Jan 28. pii: jnumed.115.168385.
    PubMed     Text format     Abstract available


  39. FENDLER WP, Lechner H, Todica A, Paprottka KJ, et al
    Safety, efficacy and prognostic factors after radioembolization of hepatic metastases from breast cancer: A large single center experience in 81 patients.
    J Nucl Med. 2016 Jan 7. pii: jnumed.115.165050.
    PubMed     Text format     Abstract available


    December 2015
  40. LIN CY, Lin CL, Huang WS, Kao CH, et al
    Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving I-131 Treatment: A Nationwide Population-based Cohort Study.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.164830.
    PubMed     Text format     Abstract available


  41. GROHEUX D, Biard L, Giacchetti S, Teixeira L, et al
    18FDG-PET/CT for the early evaluation of response to neoadjuvant treatment in triple negative breast cancer: influence of the chemotherapy regimen.
    J Nucl Med. 2015 Dec 23. pii: jnumed.115.163907.
    PubMed     Text format     Abstract available


  42. ARULAPPU A, Battle M, Eisenblaetter M, McRobbie G, et al
    c-Met PET Imaging Detects Early Stage Loco-Regional Recurrence of Basal-Like Breast Cancer.
    J Nucl Med. 2015 Dec 3. pii: jnumed.115.164384.
    PubMed     Text format     Abstract available


    September 2015
  43. MINAMIMOTO R, Loening A, Jamali M, Barkhodari A, et al
    Prospective Comparison of 99mTc MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT and Whole-Body MRI in Patients with Breast and Prostate Cancers.
    J Nucl Med. 2015 Sep 24. pii: jnumed.115.162610.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: